Skip to content

Aneurysm Packing With the Expandable TrelliX Coil System - A Prospective Safety Study

Aneurysm Packing With the Expandable TrelliX Coil System - A Prospective Safety Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03988062
Acronym
APEX-FIH
Enrollment
13
Registered
2019-06-17
Start date
2018-11-21
Completion date
2022-05-31
Last updated
2025-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ruptured or Unruptured Cerebral Aneurysms

Brief summary

APEX-FIH is a first-in-human, open-label prospective multicenter study of the TrelliX Embolic Coil System for use in embolization of the medium to large, ruptured or unruptured cerebral aneurysms

Interventions

DEVICETrelliX Embolic Coil System

Embolic coil with shape memory polymer

Sponsors

Shape Memory Medical, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Subject age ≥18 and ≤80 years with a diagnosis of a ruptured or unruptured intracranial aneurysm judged suitable for selective endovascular treatment by coil occlusion during single procedure * Aneurysm size \[largest measurement from the cross sectional images to determine overall aneurysm size, not just the lumen) ≥5 mm and ≤16mm * If ruptured aneurysm: either WFNS grade 1 or 2, or Hunt and Hess 1 or 2 * If unruptured aneurysm: Subject grade Modified Rankin Scale mRS 0 - 2 * Investigator plans to use ≥70% in volume TrelliX coils to fill target aneurysm

Exclusion criteria

* Prior treatment (surgical or endovascular) of the target aneurysm * Planned treatment of multiple aneurysms in index procedure * Planned use of other modified coils (Matrix, HydroCoil or fibered coils) * Planned use of liquid embolic material * Life expectancy less than 12 months * Presence of arteriovenous malformation * Fusiform, mycotic, traumatic, or tumoral aneurysms * Intended or planned aneurysm treatment by parent vessel occlusion * Clipping or endovascular treatment of another intracranial aneurysm performed within 30 days before or planned within 30 days following the index procedure

Design outcomes

Primary

MeasureTime frameDescription
Safety - Serious adverse events30 daysRate of freedom from incidence of serious adverse events related to the study
Efficacy - Angiographic occlusionImmediateRate of angiographic occlusion based on Raymond-Ray grading scale \[1 No filling of aneurysm neck or dome; 2 Residual filling of aneurysm neck, not dome; 3 Residual filling of aneurysm neck and dome (worst outcome)\]

Countries

Chile

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026